World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages

Natsuki Hattori, Yuichi Hirose, Hikaru Sasaki, Shunsuke Nakae, Saeko Hayashi, Shigeo Oba, Kazuhide Adachi, Takuro Hayashi, Yuya Nishiyama, Mitsuhiro Hasegawa, Masato Abe

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recent investigations revealed genetic analysis provides important information in management of gliomas, and we previously reported grade II–III gliomas could be classified into clinically relevant subgroups based on the DNA copy number aberrations (CNAs). To develop more precise genetic subgrouping, we investigated the correlation between CNAs and mutational status of the gene encoding isocitrate dehydrogenase (IDH) of those tumors. We analyzed the IDH status and CNAs of 174 adult supratentorial gliomas of astrocytic or oligodendroglial origin by PCR-based direct sequencing and comparative genomic hybridization, respectively. We analyzed the relationship between genetic subclassification and clinical features. We found the most frequent aberrations in IDH mutant tumors were the combined whole arm-loss of 1p and 19q (1p/19q codeletion) followed by gain on chromosome arm 7q (+7q). The gain of whole chromosome 7 (+7) and loss of 10q (−10q) were detected in IDH wild-type tumors. Kaplan–Meier estimates for progression-free survival showed that the tumors with mutant IDH, −1p/19q, or +7q (in the absence of +7p) survived longer than tumors with wild-type IDH, +7, or −10q. As tumors with +7 (IDH wild-type) showed a more aggressive clinical nature, they are probably not a subtype that developed from the slowly progressive tumors with +7q (IDH mutant). Thus, tumors with a gain on chromosome 7 (mostly astrocytic) comprise multiple lineages, and such differences in their biological nature should be taken into consideration during their clinical management.

Original languageEnglish
Pages (from-to)1159-1164
Number of pages6
JournalCancer Science
Volume107
Issue number8
DOIs
Publication statusPublished - 01-08-2016

Fingerprint

Isocitrate Dehydrogenase
Astrocytoma
Neoplasms
Chromosomes, Human, Pair 7
Glioma
Information Management
Comparative Genomic Hybridization
Disease-Free Survival
Chromosomes
Polymerase Chain Reaction
DNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hattori, Natsuki ; Hirose, Yuichi ; Sasaki, Hikaru ; Nakae, Shunsuke ; Hayashi, Saeko ; Oba, Shigeo ; Adachi, Kazuhide ; Hayashi, Takuro ; Nishiyama, Yuya ; Hasegawa, Mitsuhiro ; Abe, Masato. / World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages. In: Cancer Science. 2016 ; Vol. 107, No. 8. pp. 1159-1164.
@article{20762a7d0e7a450da2b32f7b6a61b173,
title = "World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages",
abstract = "Recent investigations revealed genetic analysis provides important information in management of gliomas, and we previously reported grade II–III gliomas could be classified into clinically relevant subgroups based on the DNA copy number aberrations (CNAs). To develop more precise genetic subgrouping, we investigated the correlation between CNAs and mutational status of the gene encoding isocitrate dehydrogenase (IDH) of those tumors. We analyzed the IDH status and CNAs of 174 adult supratentorial gliomas of astrocytic or oligodendroglial origin by PCR-based direct sequencing and comparative genomic hybridization, respectively. We analyzed the relationship between genetic subclassification and clinical features. We found the most frequent aberrations in IDH mutant tumors were the combined whole arm-loss of 1p and 19q (1p/19q codeletion) followed by gain on chromosome arm 7q (+7q). The gain of whole chromosome 7 (+7) and loss of 10q (−10q) were detected in IDH wild-type tumors. Kaplan–Meier estimates for progression-free survival showed that the tumors with mutant IDH, −1p/19q, or +7q (in the absence of +7p) survived longer than tumors with wild-type IDH, +7, or −10q. As tumors with +7 (IDH wild-type) showed a more aggressive clinical nature, they are probably not a subtype that developed from the slowly progressive tumors with +7q (IDH mutant). Thus, tumors with a gain on chromosome 7 (mostly astrocytic) comprise multiple lineages, and such differences in their biological nature should be taken into consideration during their clinical management.",
author = "Natsuki Hattori and Yuichi Hirose and Hikaru Sasaki and Shunsuke Nakae and Saeko Hayashi and Shigeo Oba and Kazuhide Adachi and Takuro Hayashi and Yuya Nishiyama and Mitsuhiro Hasegawa and Masato Abe",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/cas.12969",
language = "English",
volume = "107",
pages = "1159--1164",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

Hattori, N, Hirose, Y, Sasaki, H, Nakae, S, Hayashi, S, Oba, S, Adachi, K, Hayashi, T, Nishiyama, Y, Hasegawa, M & Abe, M 2016, 'World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages', Cancer Science, vol. 107, no. 8, pp. 1159-1164. https://doi.org/10.1111/cas.12969

World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages. / Hattori, Natsuki; Hirose, Yuichi; Sasaki, Hikaru; Nakae, Shunsuke; Hayashi, Saeko; Oba, Shigeo; Adachi, Kazuhide; Hayashi, Takuro; Nishiyama, Yuya; Hasegawa, Mitsuhiro; Abe, Masato.

In: Cancer Science, Vol. 107, No. 8, 01.08.2016, p. 1159-1164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - World Health Organization grade II–III astrocytomas consist of genetically distinct tumor lineages

AU - Hattori, Natsuki

AU - Hirose, Yuichi

AU - Sasaki, Hikaru

AU - Nakae, Shunsuke

AU - Hayashi, Saeko

AU - Oba, Shigeo

AU - Adachi, Kazuhide

AU - Hayashi, Takuro

AU - Nishiyama, Yuya

AU - Hasegawa, Mitsuhiro

AU - Abe, Masato

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Recent investigations revealed genetic analysis provides important information in management of gliomas, and we previously reported grade II–III gliomas could be classified into clinically relevant subgroups based on the DNA copy number aberrations (CNAs). To develop more precise genetic subgrouping, we investigated the correlation between CNAs and mutational status of the gene encoding isocitrate dehydrogenase (IDH) of those tumors. We analyzed the IDH status and CNAs of 174 adult supratentorial gliomas of astrocytic or oligodendroglial origin by PCR-based direct sequencing and comparative genomic hybridization, respectively. We analyzed the relationship between genetic subclassification and clinical features. We found the most frequent aberrations in IDH mutant tumors were the combined whole arm-loss of 1p and 19q (1p/19q codeletion) followed by gain on chromosome arm 7q (+7q). The gain of whole chromosome 7 (+7) and loss of 10q (−10q) were detected in IDH wild-type tumors. Kaplan–Meier estimates for progression-free survival showed that the tumors with mutant IDH, −1p/19q, or +7q (in the absence of +7p) survived longer than tumors with wild-type IDH, +7, or −10q. As tumors with +7 (IDH wild-type) showed a more aggressive clinical nature, they are probably not a subtype that developed from the slowly progressive tumors with +7q (IDH mutant). Thus, tumors with a gain on chromosome 7 (mostly astrocytic) comprise multiple lineages, and such differences in their biological nature should be taken into consideration during their clinical management.

AB - Recent investigations revealed genetic analysis provides important information in management of gliomas, and we previously reported grade II–III gliomas could be classified into clinically relevant subgroups based on the DNA copy number aberrations (CNAs). To develop more precise genetic subgrouping, we investigated the correlation between CNAs and mutational status of the gene encoding isocitrate dehydrogenase (IDH) of those tumors. We analyzed the IDH status and CNAs of 174 adult supratentorial gliomas of astrocytic or oligodendroglial origin by PCR-based direct sequencing and comparative genomic hybridization, respectively. We analyzed the relationship between genetic subclassification and clinical features. We found the most frequent aberrations in IDH mutant tumors were the combined whole arm-loss of 1p and 19q (1p/19q codeletion) followed by gain on chromosome arm 7q (+7q). The gain of whole chromosome 7 (+7) and loss of 10q (−10q) were detected in IDH wild-type tumors. Kaplan–Meier estimates for progression-free survival showed that the tumors with mutant IDH, −1p/19q, or +7q (in the absence of +7p) survived longer than tumors with wild-type IDH, +7, or −10q. As tumors with +7 (IDH wild-type) showed a more aggressive clinical nature, they are probably not a subtype that developed from the slowly progressive tumors with +7q (IDH mutant). Thus, tumors with a gain on chromosome 7 (mostly astrocytic) comprise multiple lineages, and such differences in their biological nature should be taken into consideration during their clinical management.

UR - http://www.scopus.com/inward/record.url?scp=84982103490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982103490&partnerID=8YFLogxK

U2 - 10.1111/cas.12969

DO - 10.1111/cas.12969

M3 - Article

C2 - 27196377

AN - SCOPUS:84982103490

VL - 107

SP - 1159

EP - 1164

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -